IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 394
EU - Europa 359
AS - Asia 91
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 849
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 393
SE - Svezia 202
IT - Italia 85
CN - Cina 55
RU - Federazione Russa 28
SG - Singapore 22
FI - Finlandia 18
IE - Irlanda 12
IN - India 10
DE - Germania 8
PH - Filippine 4
CZ - Repubblica Ceca 3
NL - Olanda 2
TN - Tunisia 2
ZA - Sudafrica 2
CA - Canada 1
EU - Europa 1
FR - Francia 1
Totale 849
Salva come PNG Salva come JPEG
Città #
Lawrence 88
Princeton 88
New York 72
Shanghai 35
Boardman 30
Milan 29
Ashburn 28
Helsinki 18
Singapore 13
Dublin 12
Moscow 7
Monza 5
Pune 5
Saint Louis 5
Quezon City 4
Seattle 4
Washington 4
Angera 3
Rome 3
Vittoria 3
Borås 2
Duchcov 2
Durban 2
Forlì 2
Padova 2
Panchkula 2
Segrate 2
Torre Del Greco 2
Trieste 2
Tualatin 2
Varedo 2
Verona 2
Amsterdam 1
Campodolcino 1
Cuneo 1
Dalmine 1
Faenza 1
Hanover 1
Lainate 1
Lecco 1
Madignano 1
Messina 1
Mountain View 1
Munich 1
Paliano 1
Perugia 1
Pisa 1
Queens 1
Redwood City 1
San Sperate 1
Santa Maria A Monte 1
Torino 1
Totale 500
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 45
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 32
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 27
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 23
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 20
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 19
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 19
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 18
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 18
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 18
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 17
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 17
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 15
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 15
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 15
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 14
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 14
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 14
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 14
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 13
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 13
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 13
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 13
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 13
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 13
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 13
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 12
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 12
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 11
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 11
Bictegravir 11
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 11
FAILURE TO DARUNAVIR/RITONAVIR CAN EITHER INCREASE OR DECREASE TIPRANAVIR/RITONAVIR GENOTYPIC RESISTANCE SCORE IN HIGHLY TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS 11
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels 10
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 10
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians 10
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 10
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 9
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 9
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy 9
Cerebrospinal fluid markers in long-term atazanavir/ritonavir monotherapy 9
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 9
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 9
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 9
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 9
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 9
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 9
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies 8
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL 8
Immune recovery and T cell subset analysis during effective treatment with maraviroc 8
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 8
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 8
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 8
LONG TERM CD4 RECOVERY IN FULLY SUPPRESSED SUBJECTS TREATED WITH FIRST LINE HAART IS INFLUENCED BY TIME TO REACH UNDETECTABILITY 8
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 7
Immortal time bias: authors' reply 7
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results 7
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies 7
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial 7
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis 7
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 7
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 7
High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects 7
HIV Glasgow 2018, 28-31 October 2018, Glasgow, UK 7
PHENOTYPIC PROFILES OF HIV-1 INTEGRASE GENE EVOLUTION DURING RALTEGRAVIR FAILURE 7
Inflammation burden score in multidrug-resistant HIV-1 infection 6
Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir 6
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 6
Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy 6
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 6
Darunavir for the treatment of HIV infection 6
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 6
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 6
Pharmacotherapeutic management of HIV in transplant patients 6
Influence of gender in predicting CCR5 coreceptor usage 6
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 5
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 5
Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression 5
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 5
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 5
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium 5
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies 4
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up 4
Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk 4
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. 4
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 4
Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine 4
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients 4
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 4
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 4
Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat 4
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLauthors response 4
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment 4
Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: Review of the literature and suggestions for a friendly use 4
Management of HIV infection after triple class failure 3
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 3
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir" 3
Predictors of lack of serological response to syphilis treatment in HIV-infected subjects 2
Totale 960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.742
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 5 0 0 0 0 0 0 0 0 0 0 0
2020/202136 0 0 0 5 0 10 1 17 2 0 1 0
2021/202269 0 0 0 18 9 9 2 6 6 4 9 6
2022/2023410 190 89 24 4 7 35 18 27 15 0 0 1
2023/2024354 6 13 54 21 36 100 5 34 1 4 25 55
2024/202535 35 0 0 0 0 0 0 0 0 0 0 0
Totale 960